Clinical Outcomes of Hepatitis B Virus–Related Hepatocellular Carcinoma Patients with Undetectable Serum HBV DNA Levels
Tóm tắt
Từ khóa
Tài liệu tham khảo
Kim JH, Sinn DH, Kim K et al. Lamivudine versus Entecavir for Newly Diagnosed Hepatitis B Virus-Related Hepatocellular Carcinoma. Gut Liver. 2016;10:939–947.
Kim BH, Lim YS, Kim EY et al. Temporal improvement in survival of patients with hepatocellular carcinoma in a hepatitis B virus-endemic population. J Gastroenterol Hepatol. 2018;33:475–483.
Cho H, Ahn H, Lee DH et al. Entecavir and tenofovir reduce hepatitis B virus-related hepatocellular carcinoma recurrence more effectively than other antivirals. J Viral Hepat. 2018;25:707–717.
Lee HW, Sinn DH, Kang W et al. Cause of Mortality for Hepatocellular Carcinoma Patients who were Diagnosed within the Milan Criteria. J Liver Cancer. 2016;16:101–107.
Korean Liver Cancer Association National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver. 2019;13:227–299.
Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol. 2019;25:93–159.
European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–398.
Terrault NA, Lok ASF, McMahon BJ et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560–1599.
Jang JW. Hepatitis B virus reactivation in patients with hepatocellular carcinoma undergoing anti-cancer therapy. World J Gastroenterol. 2014;20:7675–7685.
Jang JW, Kwon JH, You CR et al. Risk of HBV reactivation according to viral status and treatment intensity in patients with hepatocellular carcinoma. Antivir Ther. 2011;16:969–977.
Huang G, Lai EC, Lau WY et al. Posthepatectomy HBV reactivation in hepatitis B-related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV-DNA levels. Ann Surg. 2013;257:490–505.
Xie ZB, Wang XB, Fu DL, Zhong JH, Yang XW, Li LQ. Postoperative hepatitis B virus reactivation in hepatitis B virus-related hepatocellular carcinoma patients with hepatitis B virus DNA levels <500 copies/mL. Onco Targets Ther. 2016;9:4593–4603.
Sohn W, Paik YH, Cho JY et al. Influence of hepatitis B virus reactivation on the recurrence of HBV-related hepatocellular carcinoma after curative resection in patients with low viral load. J Viral Hepat. 2015;22:539–550.
Sohn W, Paik YH, Lee MW et al. Predisposing factors for recurrence of HBV-related small hepatocellular carcinoma after percutaneous radiofrequency ablation. Scand J Gastroenterol. 2014;49:373–380.
Yeo W, Lam KC, Zee B et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol. 2004;15:1661–1666.
Jang JW, Choi JY, Bae SH et al. Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J Hepatol. 2004;41:427–435.
Jun BG, Kim YD, Kim SG, et al. Hepatitis B virus reactivation after radiotherapy for hepatocellular carcinoma and efficacy of antiviral treatment: A multicenter study. PLoS One. 2018;13:e0201316.